Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
C.M. Grim, C.E. Grim.
Blood pressure measurement.
Hypertension Primer, pp. 295-298
[2.]
G.A. Mansoor, W.B. White.
White-coat hypertension. a.
Hypertension: A Companion to Brenner and Rector’s The Kidney, pp. 314-322
[3.]
O.A. Carretero, S. Oparil.
Essential hypertension. Part I: Definition and etiology.
Circulation, 101 (2000), pp. 329-335
[4.]
Joint National Committee. The Sixth Report of the Joint National Committe on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Arch Intern Med, 157 (1997), pp. 2413-2445
[5.]
Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.
J Hypertens, 17 (1999), pp. 151-183
[6.]
S. Baker, P. Priest, R. Jackson.
Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated.
BMJ, 320 (2000), pp. 680-685
[7.]
T.A. Kotchen, J.M. Kotchen.
Lifestyle modifications.
Hypertension Primer, pp. 339-341
[8.]
T.A. Kotchen, D.A. McCarron.
for the Nutrition Committee. Dietary electrolytes and blood pressure. A statement for healthcare professionals from the American Heart Association Nutrition Committee.
Circulation, 98 (1998), pp. 613-617
[9.]
O.A. Carretero, S. Oparil.
Essential hypertension. Part II: Treatment.
Circulation, 101 (2000), pp. 446-453
[10.]
M. Weber.
Emerging treatments for hypertension: potential role for vasopeptidase inhibition.
Am J Hypertens, 12 (1999), pp. 139-147
[11.]
Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure-lowering drugs: results of prospectively designed overviews of randomised trials.
Lancet, 355 (2000), pp. 1955-1964
[12.]
The Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
N Engl J Med, 342 (2000), pp. 145-153
[13.]
M.N. Hill.
Adherence to antihypertensive treatment.
Hypertension Primer, pp. 348-351
[14.]
C. Lenfant, E.J. Roccella.
A call to action for more aggressive treatment of hypertension.
J Hypertens, 17 (1999), pp. 3-7
[15.]
L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, S. Julius, et al.
Effects of intensive blood-pressure lowering and lowdose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
[16.]
S.G. Sheps.
Overview of JNC VI: new directions in the management of hypertension and cardiovascular risk.
Am J Hypertens, 12 (1999), pp. 65-72
[17.]
J.M. Neutel, D.G.H. Smith, M.A. Weber.
Low-dose combination therapy: an important first-line treatment in the management of hypertension.
Am J Hypertens, 14 (2001), pp. 286-292
[18.]
B.J. Materson.
Combination therapy as the initial drug treatment for hypertension: when is it appropriate?.
Am J Hypertens, 14 (2001), pp. 293-295
[19.]
D.G. Vidt.
Resistant hypertension.
Hypertension: A Companion to Brenner and Rector’s The Kidney, pp. 564-572
Copyright © 2001. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.